Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Lepidico

    MCap

    AUD107m

    Last close

    AUD0.02

    ▲ 0.01 (100.00%)

    Silver Spruce Resources

    MCap

    CAD5m

    Last close

    CAD0.03

    ▲ 0.01 (50.00%)

    Context Therapeutics

    MCap

    USD16m

    Last close

    USD1.00

    ▲ 0.32 (47.06%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

Abliva (OMX: ABLI)

Currency in -

Last close As at 06/02/2023

-0.17

▲ −0.01 (−5.56%)

Market capitalisation

SEK195m

Edison Investment Research is terminating coverage on Abliva. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

 

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare

Abliva — IND approved by the FDA, preparing for Ph II/III

Healthcare

Abliva — KL1333 ready for pivotal Phase II/III trial

Healthcare

Abliva — New strategic investor on board and CMD

Healthcare

NeuroVive Pharmaceutical — Rights issue and focus on core assets
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.4) (11.9) (72.7)
Relative (0.9) (20.7) (63.8)
52 week high/low SEK0.6/SEK0.2

Financials

Abliva is a Swedish biotech company with deep expertise in mitochondrial medicine. Its focus area is primary mitochondrial diseases with lead assets KL1333, an NAD+ modulator (Phase II/III ready), and NV354, a succinate prodrug (preclinical). It plans to start a pivotal Phase II/III trial with KL1333 in selected primary mitochondrial disorders this year.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021A 0.2 (117.9) (120.4) (34.44) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A

Research

View All

Thematics

View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free